- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Frontline Darovasertib Plus Crizotinib Shows Clinical Efficacy in Metastatic Uveal Melanoma
October 28th 2025, 2:04pm
Darovasertib plus crizotinib improved OS to 21.1 months and boosted response rates in first-line metastatic uveal melanoma vs historical approaches.
VERITAC-2 PRO Data Support Potential of Vepdegestrant in ESR1-Mutated ER+ Advanced Breast Cancer
October 28th 2025, 1:23pm
Vepdegestrant maintained QOL and reduced risk of symptom deterioration vs fulvestrant in ESR1-mutated ER-positive, HER2-negative advanced breast cancer.
ESMO 2025 Breast Cancer Data May Redefine Treatment Standards Across Patient Subgroups
October 27th 2025, 1:00pm
Revisit the top data and presentations in breast cancer from the 2025 ESMO Congress.
Perioperative Durvalumab Plus FLOT Generates OS Benefit in Gastric/GEJ Adenocarcinoma
October 26th 2025, 10:00am
Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.
ctDNA Clearance With Adjuvant Therapy Is Associated With Improved DFS in CRC
October 25th 2025, 10:00am
Adjuvant therapy was associated with ctDNA clearance and improved DFS in patients with resectable stage I to IV CRC.
Saruparib Plus an ARPI Shows Activity, Tolerability in Metastatic Prostate Cancer
October 24th 2025, 12:00pm
Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.
Cadonilimab Plus Chemo Retains Clinically Meaningful Survival Advantage in Frontline Gastric/GEJ Adenocarcinoma
October 23rd 2025, 1:00pm
First-line cadonilimab plus chemotherapy demonstrated long-term efficacy benefits vs chemotherapy alone in patients with advanced gastric or GEJ adenocarcinoma.
Trastuzumab Rezetecan Displays PFS Benefit Vs Pyrotinib Plus Capecitabine in Pretreated HER2+ Breast Cancer
October 23rd 2025, 12:00pm
Trastuzumab rezetecan reduced the risk of disease progression or death by 78% vs pyrotinib plus capecitabine in pretreatedHER2+ advanced breast cancer,
Atezolizumab Plus BCG Does Not Improve EFS Vs BCG Alone in BCG-Naive NMIBC
October 22nd 2025, 12:00pm
Atezolizumab plus BCG did not extend EFS vs BCG alone in BCG-naive, high-risk non–muscle invasive bladder cancer.
Pinpointing Pivotal Prostate Cancer Data With Drs Agarwal and Shore
October 21st 2025, 8:00pm
OncLive News Network: On Location at ESMO 2025
Neeraj Agarwal, MD, FASCO, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in prostate cancer presented during the 2025 ESMO Congress.
Buparlisib Plus Paclitaxel Fails to Yield OS Benefit in PD-1/PD-L1–Pretreated HNSCC
October 21st 2025, 2:03pm
ESMO Congress: Head and Neck Cancer
Buparlisib plus paclitaxel did not show an improvement in OS vs paclitaxel alone in PD-1/PD-L1–pretreated recurrent/metastatic HNSCC.
Alternative Docetaxel Regimen Plus Darolutamide/ADT Lowers Toxicity in mHSPC
October 21st 2025, 12:00pm
A reduced docetaxel regimen helped lower rates of AEs when combined with daolutamide and ADT in mHSPC.
Breaking Down the Data in Bladder Cancer With Drs Aggen, Grivas, and Shore
October 21st 2025, 3:30am
OncLive News Network: On Location at ESMO 2025
David H. Aggen, MD, PhD, Petros Grivas, MD, PhD, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in bladder cancer presented during the 2025 ESMO Congress.
Frontline EIK1001 Plus Chemoimmunotherapy Stimulates Antitumor Activity in Advanced NSCLC
October 20th 2025, 9:56pm
EIK1001 plus pembrolizumab and chemo showed a 64% ORR and manageable safety in first-line stage IV NSCLC, per phase 2 TeLuRide-005 data.
Zabilugene Almadenorepvec Plus SOC Therapy Yields OS Benefit in Untreated Metastatic PDAC
October 20th 2025, 9:31pm
Zabilugene almadenorepvec plus SOC therapy was active in patients with treatment-naive metasatic PDAC.
Zanzalintinib Plus Atezolizumab Improves OS in Previously Treated Metastatic CRC
October 20th 2025, 8:58pm
Zanzalintinib plus atezolizumab demonstrate potential chemotherapy-free option in previously treated metastatic CRC.
NADINA Trial Favors Neoadjuvant Nivolumab/Ipilimumab in Resectable Stage III Melanoma
October 20th 2025, 8:25pm
Neoadjuvant nivolumab plus ipilimumab proved superior to adjuvant nivolumab alone with longer follow-up data from the NADINA trial in stage III melanoma.
ctDNA-Guided Adjuvant Atezolizumab Boosts DFS, OS in Muscle-Invasive Bladder Cancer
October 20th 2025, 8:17pm
Adjuvant atezolizumab improved DFS and OS in patients with muscle-invasive bladder cancer who tested positive for ctDNA after radical cystectomy.
CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC
October 20th 2025, 7:59pm
Nivolumab plus ipilimumab improved PFS and response rates vs nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns.
Camrelizumab Plus Famitinib Extends PFS vs Chemotherapy in First-Line Metastatic Cervical Cancer
October 20th 2025, 7:45pm
ESMO Congress: Gynecologic Cancers
Camrelizumab plus famitinib led to superior PFS and OS outcomes vs chemotherapy in frontline recurrent/metastatic cervical cancer.